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Summary
Purpose: To describe the prevalence and nature of epileptic seizure disorders in a
typical UK prison and compare the care offered to prisoners to the recommendations
of the National Institute for Clinical Excellence (NICE).
Methods: Over a 14-month period, all prisoners identified as having epilepsy were
registered by prison primary healthcare services at a category ‘C’ prison holding 640
male adults. Prison and National Health Service health records were reviewed,
prisoners were re-assessed by members of a specialist secondary care service based
in the local general hospital NHS.
Results: Twenty-six prisoners were thought to have epilepsy. 61.5% of diagnoses had
not been made by epilepsy specialists, 73.1% had uncontrolled seizures, only 19.2%
had had computed tomography, none magnetic resonance imaging. At review, 30.8%
of prisoners were thought to require neuroimaging, 19.2% cardiac investigations. The
diagnosis of epilepsy was confirmed in only 57.9% of those prisoners considered to
have the condition by prison healthcare services. 53.8% of those prisoners confirmed
as having epilepsy had not had a medical review in the past 12 months; 63.2% required
a change in their antiepileptic drugs (AEDs).
Conclusion: Although the prevalence of epilepsy in this prison population appeared
high at first sight, a critical review of the diagnoses reduced the difference to the
prevalence of epilepsy in the population at large. Fewer prisoners than expected
achieved seizure control. Collaboration with specialist epilepsy services was poor.* Corresponding author. Tel.: +44 114 2712306; fax: +44 114 2713158.
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There were significant discrepancies between the healthcare provision in prison and
the NICE epilepsy guidelines.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
The primary purpose of a prison is to detain people
denied their liberty by the application of the law.
Prisons are not intended to reduce prisoners’ access
to healthcare. In fact, it is established government
policy in the UK that healthcare provision for prison-
ers should meet the standards developed for the
population at large.1 In the UK the National Institute
for Clinical Excellence (NICE) has been charged with
developing such standards. In 2004 it published
guidelines for the diagnosis and management of
the epilepsies in adults in primary and secondary
care.2 The recommendations in these guidelines are
graded according to the level of supporting evidence
(see Table 1).
We were concerned about the many barriers,
which exist to the provision of optimum epilepsy
healthcare in prisons (including the reluctance of
professionals to venture into the custodial environ-
ment, lack of clear referral routes, and reluctance
of hospital-based services to respond to referrals
from a prison or to provide outreach services). We
undertook this audit to describe the prevalence and
nature of seizure disorders in a typical UK prison and
to examine how the standards of diagnosis and
management of epilepsy in prison compare to the
NICE guidelines for this disorder.Methods
The audit resulted from a collaboration of a Clinical
Nurse Specialist (CNS) in Epilepsy based at the local
NHS hospital (PT) and a prison nurse based with the
client group (JC). The prisoners were identified andTable 1 Grading of recommendations by the UK National
Grade Definition
A Directly based on category I evidence (meta-a
least one RCT)
B Directly based on category II evidence (at leas
least one other quasi-experimental study) or e
C Directly based on category III evidence (non-ex
category II evidence
D Directly based on category IV evidence (expert
authorities) or extrapolated from category III e
N Recommendation based on NICE guideline or te
GPP Good practice point based on the clinical expereviewed for the purpose of this audit between June
2004 and August 2005. The audit was approved by
South West Staffordshire Primary Trust.
Setting
The audit was carried out in a medium level security
(category C) prison, housing 640 sentenced male
adults. The prison was split into two distinct units
with separate healthcare provision. In line with
common prison practice, prisoners were placed in
these units depending on their behaviour and/or the
nature of their conviction (e.g. those convicted of
sexual offences have to be segregated for their own
protection). Prison healthcare was fragmented
further by separate regimes within individual wings,
with resources allocated according to the perceived
risk and need of the prisoner group. Healthcare was
delivered by one part-time Medical Officer (a Gen-
eral Practitioner), and a small team comprising of a
mixture of Health Care Officer’s (HCO’s, prison offi-
cers who have completed a short course in general
health care) and Registered Nurses (RN’s). There
were no inpatient facilities, and healthcare staff
were based on the different wings between the
hours of 07.30 and 20.45. There was no resident
medical cover overnight.
Case identification
During the audit period the treatment sheets of
all prisoners passing through the institution were
examined for evidence of Anti Epileptic Drug (AED)
prescribing. The results of this search were cross-
referenced against the Inmate Medical Record (IMR)
to ensure the AED prescribing was related to seizureInstitute of Clinical Excellence
nalysis of randomized controlled trials (RCTs) or at
t one controlled trial without randomization or at
xtrapolated from category I evidence
perimental descriptive studies) or extrapolated from
committee reports or clinical experience of respected
vidence
chnology appraisal
rience of the Guideline Development Group
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control aggressive behaviour). Prisoners were also
included in this audit if they were not taking AEDs
but known to have seizures.
Data collection
Data were extracted from the treatment sheets and
IMR. All prisoners identified as having a possible
seizure disorder were assessed face-to-face by the
prison nurse (JC) and (if possible) the Clinical Nurse
Specialist in Epilepsy (CNS, PT). The CNS was con-
sidered competent in the diagnosis of patients with
epilepsy by his National Health Service (NHS) super-
visors and routinely diagnoses epilepsy in his NHS
role. Information about previous investigations and
current medical treatment gathered from prisoners
or the IMR were crosschecked against the NHS med-
ical records if available.Results
Demographic variables
During the course of the audit, the prison’s popula-
tion fluctuated as prisoners moved around the prison
system, or were released back into the community.
However, the prevalence of prisoners considered to
have epilepsy remained virtually static during the
period in which this service audit was undertaken. A
‘snap shot’ of the prison’s population in June 2004Table 2 Demographic details of prisoners with sei-
zures identified in one UK prison over a 14-month
period
Prisoners identified
(N = 26)
Median age (range) 31 (22—49) years
Ethnicity White 21/26 (81%)
Black 3/26 (12%)
Asian 2/26 (8%)
Nature of crime Acquisition 18/26
(69%)
Sexual 4/26 (15%)
Violence 3/26 (12%)
Drugs 1/26 (4%)
Median length of
sentence (range)
4.75 (2—9) years
Median number of previous
convictions (range)
15 (0—50)
Median number of
adjudications (range)
3 (0—21)
Prisoners with
security marker
11/26 (42.3%)revealed a total of 641 prisoners, of which 13 were
considered to have epilepsy and were receiving
antiepileptic medication (2%). Over the whole per-
iod of the audit 26 prisoners with presumed epilepsy
were identified. (see Table 2 for further demo-
graphic information). 18/26 (69.2%) were identified
because they were taking AEDs, 8/26 (30.8%)
because they were known to have seizures although
they were untreated. Whereas all of these prisoners
were assessed by the prison nurse (JC) only 17/26
(65.4%) were reviewed by the CNS in epilepsy and 1/
26 (3.8%) was seen by a Consultant Neurologist. The
remaining 8/26 (30.8%) prisoners were not seen by
an epilepsy specialist because they were transferred
to other prisons (7/26) or escaped (1/26) before a
review could be arranged.
34.6% of prisoners considered to have epilepsy
were placed under a ‘‘basic regime’’, which offers
only basic privileges such as shorter domestic visits
and more limited time out of cells, and resided on
the wing with a reputation for managing those with
disruptive behaviour. Apart from the restrictions of
the basic regime, those prisoners considered to have
epilepsy were also placed under ‘epileptic restric-
tions’, which could include not being allowed to
occupy a cell which required walking upstairs
(‘locate flat’), or not being allowed to work in
particular workshops or the kitchen (‘Labour 2B’).
The majority of prisoners considered to have epi-
lepsy were placed under ‘shared cell’ restrictions,
which represents a further limitation of potential
privileges, as other prisoners who had earned
‘enhanced status’ were invariably accommodated
in single cells.
Seizure onset and frequency
7.7% of prisoners reported an age at seizure onset of
less than 10 years; 57.7% of 10 to 20; 26.9% of 20 to
30; and 7.7% of more than 30 years. The median
reported seizure frequencywas3peryear (range:1 in
8 years to 96 per year). The distribution of reported
seizure frequencies is shown in Fig. 1. 7/26 (26.9%) ofFigure 1 Distribution of seizure frequencies reported by
26 prisoners thought to have epilepsy.
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months. The seizure frequency of one prisoner was
not recorded by the CNS before he escaped from
custody, but he had reported to the prison nurse that
his seizures were not controlled.
Potential relation to illicit drug use
38.4% of prisoners reported that seizure developed
within 12 months of commencing significant sub-
stance misuse (usually cocaine and/or alcohol).
Illicit drug use often continued. Mandatory Drug
Test (MDT) records suggested recent drug use in
23.1% of the prisoners reviewed. Many prisoners also
recognized substance abuse as a trigger factor for
ongoing seizures.
Investigations
The NICE guidelines suggest timely neuroimaging for
all patients who develop epilepsy as adults, espe-
cially when there are seizures with focal features or
when seizures continue despite medication (unless
the EEG has confirmed a diagnosis of idiopathic
generalized epilepsy, recommendation category
C). They describe magnetic resonance imaging
(MRI) as the imaging investigation of choice (cate-
gory C). Only 5/26 (19.2%) of prisoners considered to
have epilepsy by the prison medical officer had
undergone a CT head scan, and this had invariably
happened prior to custody. None of the prisoners
considered to have epilepsy had been investigated
with cranial MRI. Based on the NICE guidelines
neuroimaging was required in 30.8% of prisoners.
The NICE guidelines do not recommend that all
patients with possible epilepsy should have an EEG.
However, the guidelines state that EEG examina-
tions can be used to support the diagnosis of epi-
lepsy in adults in whom the clinical history suggests
it, to help determine seizure type and syndrome and
to assess seizure recurrence risk after a single
unprovoked seizure (recommendation category C).
Only 50% of those prisoners considered to have
epilepsy by prison primary healthcare services had
had an EEG. Where EEG had been undertaken, the
results were interpreted by the referring clinician
rather than an epilepsy expert.
Diagnosis
According to the NICE guidelines the diagnosis of
epilepsy should always be made by an epilepsy
specialist (recommendation category C), and sei-
zures and seizure syndrome should be classifiedusing a multiaxial diagnostic scheme (category D).
In the prisoners, only 10/26 (38%) of the diagnoses of
epilepsy had been made by specialists. No syndro-
mic diagnoses were recorded.
The diagnosis was reviewed in 19/26 (73.1%)
prisoners who were available for face-to-face
assessment by an epilepsy specialist. Only 11/19
(57.9%) were thought to have definite epilepsy.
The diagnosis was considered doubtful in the
remaining 8/19 (42.1%): 4/19 (21.1%) were thought
to have non-epileptic seizures, 2/19 (10.5%) recur-
rent syncope, one was thought to have panic
attacks, and one drug-induced, provoked seizures.
Developmental history and psychiatric co-
morbidity
12/26 (46.2%) prisoners with seizures grew up in
care homes, an unstable or abusive family environ-
ment. The records of only 3/26 (11.5%) of prisoners
with seizures and 1/11 (9.1%) of patients with con-
firmed epilepsy made no reference to psychiatric
symptoms. The commonest problems in prisoners
with epilepsy were drug or alcohol addiction (5/11,
45.5%) and deliberate self-harm or parasuicide (3/
11, 27.3%).
Treatment
According to the NICE guidelines antiepileptic drug
treatment should be initiated by an epilepsy spe-
cialist who should also provide a plan for continua-
tion of therapy and be consulted about medication
withdrawal (recommendation category GPP). They
should be provided with an accessible point of con-
tact with the specialist services (category GPP).
None of the prisoners identified (including those
who had seen specialists in the past) had access
to specialist services at the time of the audit. Gen-
erally prisoners were prescribed monotherapy, but
2/26 (7.7%) received a combination of two or more
AEDs. The AEDs used included carbamazepine (14
prisoners, median dose 400 mg daily, range 200—
800 mg), lamotrigine (3 prisoners, median dose
200 mg daily, range 50—400 mg), phenytoin (3 pris-
oners, 300 mg daily) or sodium valproate (2 prison-
ers, 900, 1000 mg daily). The audit found that 7/26
(26.9%) prisoners were receiving AED treatment in
surprisingly low doses despite ongoing seizures
(200 mg carbamazepine/day, 50 mg lamotri-
gine/day). There was no evidence that treatment
plans had been discussed with epilepsy specialists.
Epilepsy specialist review resulted in recommended
treatment changes in 12/19 (63.2%) prisoners (with-
drawal 4/19, medication increase 4/19, medication
change 4/19). Prescribing errors were found, for
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‘‘Tegretol Retard’’ had their prescription changed
over time to read ‘Tegretol’ and were receiving
standard formulation carbamazepine preparations
twice a day.
According to the NICE guidelines patients should
receive appropriate information about all aspects of
epilepsy, which should be maintained through struc-
tured self-management, plans (category A).
Although most prisoners were self-medicating,
there was no evidence that prisoners had been
educated about these drugs or had formal manage-
ment plans. Titration programmes were poorly
understood among prison healthcare staff. AEDs
were dispensed to prisoners weekly, and titration
was often thwarted by the reluctance of healthcare
staff to dispense AEDs before the next weekly col-
lection date because they realised that AEDs were
being traded illegally within the prison. Prisoners
had no means of safely storing their medication in a
secure cabinet.
Although (with the exception of phenytoin) the
NICE guidelines do not recommend this practice
(recommendation category D), in prisoners dosages
were often adjusted according to blood levels,
rather than in response to clinical symptoms. Intra-
muscular diazepam was used for status epilepticus,
but there was no protocol for management of status
until it was introduced by the investigating team.
Lack of knowledge and training in first aid treatment
of seizures was the rule, and many prisoners
expressed anxiety about how their seizures would
bemanaged, especially at night when the prison was
placed in patrol state with limited staff observation.
The NICE guidelines recommend a regular struc-
tured review of epilepsy treatment at least once per
year and referral to specialist care if epilepsy is
inadequately controlled (category D). 14/26 (53.8%)
of prisoners had not had an epilepsy or treatment
review in the past 12 months, with the majority of
these having had no review in the past 10 years.
When they were reviewed in for this project, a
change of medication was suggested in 12/26
(46.2%) of prisoners with epilepsy. No prisoners
had been assessed for epilepsy surgery.
Advice and information
None of the prisoners with epilepsy were given
information concerning their condition, or safety
issues. Internet access was not available and no
patient information leaflets were being made
available. None of the prisoners had been given
advice concerning Sudden Unexpected Death in
Epilepsy (SUDEP), even though the prison had
experienced a death in custody related to epilepsyin recent years. 17/26 (65.4%) of the prisoners
with epilepsy had not been advised of driving
regulations in preparation for their release back
into society.Discussion
Two percent of the prison population had a diagnosis
of epilepsy or were receiving AEDs for this condition.
This suggests that the prevalence of epilepsy
amongst prisoner was increased compared to the
established prevalence of 5—10 per 1000 in the
general population.3,4 This result would be in keep-
ing with previous studies.5—11 For instance, one
study in the UK estimated a prevalence of 7.1/
1000 in prisoners and cited a prevalence of 4.5/
1000 in the general population.7 However, face-to-
face review by an epilepsy specialist nurse with
recognized competence in the diagnosis of seizure
disorders suggested that the diagnosis of epilepsy
may have been applied inappropriately in 57.9% of
prisoners. Although our case ascertainment method
would have failed to identify prisoners with epilepsy
who were not taking medication and had not dis-
closed the diagnosis, this indicates that the true
prevalence of epilepsy in the prison may be lower
than previously reported and similar to that in the
population at large. This conclusion matches
the finding of a meta-analysis of studies describing
the prevalence of epilepsy amongst prisoners which
only included studies involving a face-to-face
assessment of individual prisoners.12
The seizure frequency distribution found in the
described group of prisoners suggested that seizures
were more poorly controlled than in community-
based populations of people with epilepsy. Whereas
seizures were in remission in only 26.9% of prisoners
the equivalent figures from two UK-based primary
care studies were 53%13 and 61%14, respectively.
Over the longer term one would expect over 60%
of patients to stop having seizures with modern
antiepileptic drug treatment.15 The two most
obvious reasons for the low rates of prisoners
achieving seizure control evident from our audit
were that diagnoses were inaccurate in a high num-
ber of prisoners and that antiepileptic drugs were
used in surprisingly low doses in many cases.
Our review of the available medical records sug-
gested that prisoners often had a traumatic devel-
opmental background and (in keeping with a
previous study16) increased rates of psychiatric
co-morbidity. For instance, in one recent study
including a group of patients with epilepsy 39%
had no co-morbid psychiatric diagnosis,17 whereas
the corresponding figure in this study is less than
74 P. Tittensor et al.10%. The lifetime risk of substance abuse in patients
with epilepsy in another study was 20.1%,18 whereas
it was 45.5% here.
This audit suggests that the medical service cur-
rently offered to prisoners with epilepsy in the UK
falls short of national treatment guidelines in many
areas although it is government policy that prisoners
should receive the same level of healthcare as
members of the public at large. The discrepancies
between the NICE guidelines on the management of
the epilepsies and the health care received by
prisoners affected all aspects of medical care from
investigations, diagnosis and access to specialist
advice to treatment plans and access to information
about epilepsy.2
The UK government has been concerned about
inequalities between healthcare in prisons and the
community for a long time. Recent reforms have
addressed this problem by integrating the Prison
Medical Service into the National Health Service
(NHS).19 In 2002, this strategy culminated in the
decision to transfer the budgetary responsibility for
prison health from the Prison Service to the Depart-
ment of Health. Since April 2006 full commissioning
responsibility has been devolved to local Primary
Care Trusts (PCTs).20 Our audit suggests that the
implementation of the NICE guidelines in prisons will
be a particularly urgent and difficult task for PCTs.
One important challenge will be the development
of a better working relationship between prison
health care staff and secondary care. The NICE
guidelines recognise that the involvement of an
epilepsy specialist is important for the diagnosis
of epilepsy because a range of studies had demon-
strated misdiagnosis rates of one in four patients
thought to have epilepsy in primary care,21 or
referred to a secondary care service because of
‘‘refractory epilepsy’’.22 Whilst it is recognised that
there is a prevalent population of patients with
epilepsy in the UK who have never seen an epilepsy
specialist, the proportion of prisoners with sus-
pected epilepsy who had never seen an epilepsy
expert (61.5%) even exceeded the 55% of people
with epilepsy in a recent UK-based rural community
study who had never been seen in secondary care.14
The NICE guidelines also suggest that specialists
should be involved in starting, planning and with-
drawing antiepileptic drug treatment. To improve
the quality of diagnosis and treatment of epilepsy in
prisons, specialist services will have establish closer
working relationships with prison health care staff,
consider visiting prisons to ensure that prisoners can
be interviewed in an environment where confiden-
tiality can be assured. It is unlikely that prisoners
would volunteer a perceived connection of seizures
and ongoing substance abuse if they were ques-tioned about this in the company of prison officers
escorting them to outpatient appointments–—it
should be noted that the high rate of alcohol and
substance abuse in prisoners with epilepsy has also
been described by other authors.23,24 It is also unli-
kely that seizure witnesses could be questioned
outside prison. Given the considerable cost of send-
ing a prisoner to a hospital outpatient appointment
(approximately £250.00 plus the cost of the con-
sultation) an additional investment in specialist
outreach services covering prisons may even be
cost-effective.
One particularly urgent area requiring collabora-
tion of prison and specialist medical staff is the
improvement of the drug treatment of epilepsy in
prison. In an environment where AEDs have signifi-
cant illicit trading value, interpretation of blood
levels to check concordance may be useful. How-
ever, prison medical staff should realise that the
adjustment of medication based on the measured
values can be dangerous and does not reflect current
best practice.2 AEDs are frequently prescribed in
low doses, which are not escalated if seizures con-
tinued. Rescue medication is not used. The authors
recognise that rescue medication presents problems
in an environment where drugs are commonly
abused. Nevertheless, the prison authorities have
a duty of care and need to ensure that prisoners are
safe whilst they are in custody. This means that a
system of observation needs to be in place, which
ensures that prolonged epileptic seizures are
noticed, and that there is access to appropriate
medical help and emergencymedication if required.
Much of the input of specialist staff should be
educational. The interaction with prison staff and
prisoners during this project revealed that there was
a need to deliver training to the prisoner as a
patient, prison nursing staff, prison officers as well
as the prisoner peer group as a whole. First aid
training and awareness education should be offered
to cell mates of prisoners with epilepsy. Such mea-
sures could in some part confront the stigma of
epilepsy that remains entrenched within the prison
environment.
Prior to this project, social and lifestyle issues
related to epilepsy had not been critically reviewed
in the prison where the audit was undertaken. The
stigma of the condition was highlighted by the use of
the label ‘‘epileptic’’ being written on role boards
and added to cell door cards identifying that the
occupier had epilepsy. Issuing ‘‘identity cards’’ has
helped in this regard. Prisoners with epilepsy had
restrictions placed on their living arrangements, and
invariably had to share a cell and use the bottom
bunk irrespective of their seizure frequency, thus
eroding their perceived status. Information leaflets
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liberty and were noted to have limited relevance in
the custodial setting, especially where reading skills
are limited. The authors understand that Epilepsy
Action (a leading UK-based epilepsy charity) is cur-
rently in the process of developing better-targeted
information.Conclusion
Whilst the authors accept that their results are
based on a relatively small audit in a single prison,
they have no reason to believe that the health
provisions in the institution where the audit was
undertaken are particularly poor. The findings place
an onus on other institutions to check that their
services are superior. Improvements in the prison
health service are essential if prisons take their
rehabilitative role seriously. Although some
improvements may be made through the education
of existing staff and more efficient use of current
clinical services, it is likely that significant progress
will require additional funding. A period in prison
should not be a health hazard for people with
epilepsy but an opportunity to break out of a cycle
of seizures, stigma, low self-esteem, unemploy-
ment, substance abuse and crime.References
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